Ventrus Biosciences (VTUS) develops new treatments for gastrointestinal (GI) disorders with a lead product candidate (Diltiazem Topical Cream or VEN 307) that is currently being evaluated in the second of two planned pivotal Phase III clinical trial.
CLINICAL TRIAL CATALYSTS:
VTUS expects to report results from the second of two pivotal Phase III clinical trials (ClinicalTrials.gov ID NCT01690221) for the relief of pain associated with anal fissures during Q4 2013 to support a planned 505(b)(2) NDA filing for a novel topical formulation of an approved calcium channel blocker drug (diltiazem). Last May, EU partner S.L.A. Pharma reported positive results in the first Phase III clinical trial for VEN-307.
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: